<DOC>
	<DOCNO>NCT00561184</DOCNO>
	<brief_summary>To assess persistence antibody titer 17-18 month primary immunization two 0.5mL intramuscular ( IM ) dose H5N1 influenza vaccine contain H5N1 influenza antigen , measure Hemagglutination Inhibition ( HI ) , Single Radial Hemolysis ( SRH ) , Microneutralization ( MN ) test</brief_summary>
	<brief_title>Safety Immunogenicity Booster Dose -H5N1 Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject previously participate study V87P1 , receive booster dose day 202 Pregnant breastfeeding Receipt another vaccine investigational agent within past 4 week Surgery plan study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>H5N1 Pandemic</keyword>
</DOC>